Raymond James downgraded shares of Davita (NYSE:DVA) from an outperform rating to a market perform rating in a report published on Thursday, Briefing.com Automated Import reports.

A number of other research analysts have also recently commented on the company. Wolfe Research cut Davita from an outperform rating to a market perform rating and set a $57.00 price target on the stock. in a research note on Friday, October 25th. ValuEngine upgraded Davita from a sell rating to a hold rating in a research note on Wednesday, October 2nd. SunTrust Banks upped their price target on Davita to $72.00 and gave the stock a hold rating in a research note on Wednesday. TheStreet upgraded Davita from a c+ rating to a b- rating in a research note on Wednesday, July 24th. Finally, Robert W. Baird cut Davita from an outperform rating to a neutral rating and decreased their price target for the stock from $70.00 to $65.00 in a research note on Friday, July 26th. Nine research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The stock presently has a consensus rating of Hold and a consensus price target of $64.81.

NYSE:DVA traded up $0.66 during trading hours on Thursday, reaching $69.85. 2,446,213 shares of the stock were exchanged, compared to its average volume of 2,127,695. The company has a quick ratio of 1.10, a current ratio of 1.12 and a debt-to-equity ratio of 1.90. The business has a 50-day moving average of $58.51 and a two-hundred day moving average of $55.70. Davita has a twelve month low of $43.40 and a twelve month high of $70.51. The company has a market capitalization of $10.01 billion, a price-to-earnings ratio of 19.57, a PEG ratio of 0.62 and a beta of 1.59.

Davita (NYSE:DVA) last released its quarterly earnings results on Tuesday, November 5th. The company reported $1.53 EPS for the quarter, topping analysts’ consensus estimates of $1.24 by $0.29. Davita had a return on equity of 18.03% and a net margin of 3.68%. The company had revenue of $2.90 billion for the quarter, compared to analysts’ expectations of $2.85 billion. During the same period in the prior year, the firm earned $0.56 earnings per share. The firm’s revenue was up 2.0% compared to the same quarter last year. On average, research analysts forecast that Davita will post 5.19 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. increased its holdings in Davita by 0.5% in the second quarter. Vanguard Group Inc. now owns 13,652,940 shares of the company’s stock valued at $768,114,000 after buying an additional 64,415 shares during the last quarter. Par Capital Management Inc. increased its holdings in Davita by 40.6% in the second quarter. Par Capital Management Inc. now owns 4,159,000 shares of the company’s stock valued at $233,985,000 after buying an additional 1,201,300 shares during the last quarter. Invesco Ltd. increased its holdings in Davita by 56.2% in the second quarter. Invesco Ltd. now owns 3,662,685 shares of the company’s stock valued at $206,063,000 after buying an additional 1,317,725 shares during the last quarter. Viking Global Investors LP increased its holdings in Davita by 5.5% in the second quarter. Viking Global Investors LP now owns 2,907,034 shares of the company’s stock valued at $163,550,000 after buying an additional 151,529 shares during the last quarter. Finally, Camber Capital Management LP increased its holdings in Davita by 33.3% in the second quarter. Camber Capital Management LP now owns 2,000,000 shares of the company’s stock valued at $112,520,000 after buying an additional 500,000 shares during the last quarter. Institutional investors and hedge funds own 91.00% of the company’s stock.

About Davita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.

See Also: Most Volatile Stocks

Analyst Recommendations for Davita (NYSE:DVA)

Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.